Development of the SoloSTAR® insulin pen device: Design verification and validation

Expert Opinion on Drug Delivery

Volumn 6, Issue 1, 2009, Pages 103-112

  Bode, Andreas ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Design; Development; Device validation; Device verification; Diabetes mellitus; Engineering; Insulin pen device; Long acting insulin; Short acting insulin

Indexed keywords

INSULIN; INSULIN GLARGINE; INSULIN GLULISINE; LONG ACTING INSULIN; SHORT ACTING DRUG; ANTIDIABETIC AGENT;

CLINICAL PRACTICE; COLOR BLINDNESS; COLOR VISION; COLOR VISION DEFECT; DEVICE; DIABETES MELLITUS; DISPOSABLE EQUIPMENT; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; HAND FUNCTION; HEALTH PRACTITIONER; HUMAN; HYPOGLYCEMIA; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SKIN MANIFESTATION; VALIDATION STUDY; VISUAL ACUITY; ARTICLE; EQUIPMENT DESIGN; INSTRUMENTATION; PATIENT SATISFACTION; STATISTICS;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT SATISFACTION; VALIDATION STUDIES AS TOPIC;

EID: 64749083620     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802636187     Document Type: Review

References (29)

1. Carter J, Beillin J, Morton A, et al. Usability, participant acceptance and safety of SoloStar in a 3-month observational survey in everyday clinical practice. J Diabetes Sci Technol 2007;1(Suppl 1):A21
2. De Luise M, Beillin J, Morton A, et al. Influence of diabetes type and previous experience of pen devices on acceptance and usability of a new pen: an observational survey on SoloStar use. J Diabetes Sci Technol 2007;1(Suppl 1):A30
3. Schwartz SL, Vlajnic A. Validation of the SoloStar insulin pen. J Diabetes Sci Technol 2007;1(Suppl 1):A159
4. Roberts A, Thornley S. Health care professional-reported usability of SoloStar in a 3-month observational survey in everyday clinical practice. J Diabetes Sci Technol 2007;1(Suppl 1):A151
5. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007;4(2):165-174 •• This review reports on the key investigations during the development of SOL and highlights dose accuracy and injection force testing in comparison with two other commonly used insulin pens. (Pubitemid 46389914)
6. Owens DR. Study to compare the injection force required for the following insulin pen devices: Lilly disposable pen, Novo FlexPen, and SoloStar. J Diabetes Sci Technol 2007;1(Suppl 1):A134
7. IMS Health. IMS Midas(TM) June 2007, Quarterly insulin sales volume in units. 2007
8. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28(10):1712-1725 •• This study reports the benefits provided by insulin injection pen devices for patients converting from the vial and syringe. Importantly, the delivery of insulin using a pen device increases patient adherence to treatment, including fewer adverse medical events, such as hypoglycaemia and the requirement of emergency treatment, compared with insulin administered by means of the vial and syringe. Together with the evidence of cost effectiveness, this gives a further indication that switching from the vial and syringe to an insulin pen can provide the patient and treating physician considerable advantages in terms of the management of diabetes. (Pubitemid 44841979)
9. International Organization for Standardization. Pen-injectors for medical use - Part 1: Pen-injectors - Requirements and test methods (ISO 11608-1:2000). Geneva, Switzerland: International Organization for Standardization; December 2000
10. Aljahlan M, Lee KC, Toth E. Limited joint mobility in diabetes. Postgrad Med 1999;105(2):99-101, 5-6
11. Casanova JE, Casanova JS, Young MJ. Hand function in patients with diabetes mellitus. South Med J 1991;84(9):1111-1113
12. Rosenbloom AL. Limitation of finger joint mobility in diabetes mellitus. J Diabetes Complications 1989;3(2):77-87
13. Savas S, Koroglu BK, Koyuncuoglu HR, et al. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diabetes Res Clin Pract 2007;77(1):77-83 (Pubitemid 46590476)
14. Schady W, Abuaisha B, Boulton AJ. Observations on severe ulnar neuropathy in diabetes. J Diabetes Complications 1998;12(3):128-132 (Pubitemid 28241436)
15. Starkman HS, Gleason RE, Rand LI, et al. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann Rheum Dis 1986;45(2):130-135 • This article highlights the prevalence of limited joint mobility, a condition associated with patients with diabetes. Impairments in manual dexterity in patients with diabetes can affect the patient's ability to self-inject insulin, and is an important consideration in the development of insulin delivery devices. (Pubitemid 16162480)
16. Gehrs KM, Anderson DH, Johnson LV, et al. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 2006;38(7):450-471 (Pubitemid 44767496)
17. Whiteside MM, Wallhagen MI, Pettengill E. Sensory impairment in older adults: part 2: Vision loss. Am J Nurs 2006;106(11):52-61; quiz 61-62 (Pubitemid 44657238)
18. Aylward GW. Progressive changes in diabetics and their management. Eye 2005;19(10):1115-1118 •• This paper provides a perspective on the prevalence of diabetic retinopathy, and highlights the therapeutics available for treatment and the key unmet needs of patients with this condition. (Pubitemid 41823771)
19. Wong T, Mitchell P. The eye in hypertension. Lancet 2007;369(9559):425- 435 (Pubitemid 46188480)
20. Wong TY, Klein R, Amirul Islam FM, et al. Three-year incidence and cumulative prevalence of retinopathy: the atherosclerosis risk in communities study. Am J Ophthalmol 2007;143(6):970-976 (Pubitemid 46764650)
21. Fong DS, Barton FB, Bresnick GH. Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. Am J Ophthalmol 1999;128(5):612-617 •• This trial highlights that patients with diabetic retinopathy commonly show impairment of colour vision. The importance of this observation has implications in the development of insulin pens, such as the colour differentiation of devices to avoid medication errors. (Pubitemid 29528599)
22. de Jong PT. Age-related macular degeneration. N Engl J Med 2006;355(14):1474-1485 (Pubitemid 44511562)
23. McIntyre DA. Colour blindness: causes and effects. Chester: Dalton Publishing; 2002
24. Austin F, Cox G. Lantus SoloStar and Apidra SoloStar pen colors contributes to the differentiation by users with normal vision and by users with impaired color vision. J Diabetes Sci Technol 2007;1(Suppl 1):A4
25. Haak T, Edelman S, Walter C, et al. Comparison of usability and patient preference for the new disposable insulin device SoloStar versus Flexpen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther 2007;29(4):650-660
26. Fox C, McKinnon C, Wall A, et al. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diab Int 2002;19:104-107 (Pubitemid 34904904)
27. Petzinger RA. Diabetes aids and products for people with visual or physical impairment. Diabetes Educ 1992;18(2):121-138
28. Schreiber S, Ferlinz K, Donaubauer B. The Reliability and Usability of SoloSTAR® (SOL) Disposable Pen in Clinical Practice in Germany. Presented at the CDA/CSEM Professional Conference and Annual Meeting, Montreal, Quebec, October 15-18, 2008. Abstract 88
29. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294-1305 (Pubitemid 351172225)